Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.03. | BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | 177 | GlobeNewswire (Europe) | Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating... ► Artikel lesen | |
11.03. | BrainsWay GAAP EPS of $0.04 beats by $0.02, revenue of $11.41M beats by $0.52M | 2 | Seeking Alpha | ||
11.03. | Brainsway Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
10.03. | BrainsWay Q4 2024 Earnings Preview | 2 | Seeking Alpha | ||
12.12.24 | BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder | 1 | GlobeNewswire (USA) | ||
12.12.24 | Brainsway Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
20.11.24 | BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy | 1 | GlobeNewswire (USA) | ||
BRAINSWAY Aktie jetzt für 0€ handeln | |||||
20.11.24 | Brainsway Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
12.11.24 | BrainsWay GAAP EPS of $0.02 beats by $0.01, revenue of $10.5M beats by $0.41M | 1 | Seeking Alpha | ||
12.11.24 | BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights | 161 | GlobeNewswire (Europe) | Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON... ► Artikel lesen | |
11.11.24 | BrainsWay Q3 Earnings Preview | 1 | Seeking Alpha | ||
05.11.24 | Brainsway Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
29.10.24 | BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024 | 7 | GlobeNewswire (USA) | ||
21.10.24 | Brainsway retains Buy rating and stock target on financing deal | 1 | Investing.com | ||
21.10.24 | Brainsway behält Kaufempfehlung und Kursziel nach Finanzierungsvereinbarung bei | 3 | Investing.com Deutsch | ||
09.10.24 | BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS Systems in Taiwan and South Korea | 2 | GlobeNewswire (USA) | ||
09.10.24 | Brainsway Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
29.08.24 | BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer | 124 | GlobeNewswire (Europe) | BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments... ► Artikel lesen | |
06.08.24 | BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights | 168 | GlobeNewswire (Europe) | Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth... ► Artikel lesen | |
03.06.24 | BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression | 151 | GlobeNewswire (Europe) | BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SIEMENS HEALTHINEERS | 44,570 | -4,19 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Siemens Healthineers auf "Buy" mit einem Kursziel von 67 Euro belassen. Der Medizintechnikkonzern dürfte solide Quartalszahlen vorlegen und... ► Artikel lesen | |
CARL ZEISS MEDITEC | 48,740 | -5,91 % | Carl Zeiss Meditec, Hugo Boss, MTU Aero Engines, PVA TePla, Renk, TUI u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
ECKERT & ZIEGLER | 48,400 | -7,90 % | HAUCK AUFHÄUSER INVESTMENT BANKING stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Eckert & Ziegler auf "Buy" mit einem Kursziel von 66 Euro belassen. Als Lieferant radioaktiver Komponenten profitiere... ► Artikel lesen | |
UNITEDHEALTH | 479,70 | -0,09 % | UnitedHealth Group (UNH) - Jim Cramer Calls for Patience: 'Wait Before You Chase This Red-Hot Stock!' | ||
TELADOC HEALTH | 6,611 | -0,71 % | Teladoc Health Aktie: Wartet mehr Arbeit auf uns? | Teladoc Health steht aktuell im Zentrum bedeutender Insider-Handelsaktivitäten und strategischer Partnerschaften zur Erweiterung des Serviceangebots. Die Aktie notiert derzeit bei 7,94 Euro und verzeichnet... ► Artikel lesen | |
HIMS & HERS HEALTH | 23,780 | +0,13 % | DAX in Wartestellung vor Trump-Zöllen - Thyssen, LVMH, CoreWeave, Hims & Hers, Ralph Lauren, Tesla | Der DAX hat gestern kräftig zugelegt und den Handelstag bei 22.539 Punkten beendet. Die Vorgaben aus Übersee sind größtenteils positiv. Allerdings richtet sich die Aufmerksamkeit immer mehr auf die... ► Artikel lesen | |
ALCON | 76,63 | -7,02 % | Alcon Publishes Agenda for 2025 Annual General Meeting | Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per... ► Artikel lesen | |
RESMED | 188,00 | +0,29 % | ResMed-Direktor Peter Farrell verkauft Aktien im Wert von 439.480 US-Dollar | ||
AMBU | 14,540 | +0,97 % | Ambu A/S: Launch of Long-Term Incentive Plan for Executive Management and key employees | 31.1.2025 09:35:34 CET | Ambu A/S |
Other information disclosed according to the rules of the Exchange
Ambu A/S (Ambu) launches a new share based Long-Term Incentive Plan (LTIP) for the Executive... ► Artikel lesen | |
LIFEWARD | 1,470 | -6,37 % | Lifeward Ltd.: FDA Issues Clearance for ReWalk 7 Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
BONESUPPORT | 27,700 | +0,36 % | Bonesupport Holding Aktie: Willkommen zur Erfolgsgeschichte! | Die Bonesupport Holding Aktie verzeichnete am 22. März einen erfreulichen Tagesgewinn von 1,61% und schloss bei 30,25 EUR. Dies stellt eine positive Entwicklung dar, obwohl das Orthobiologie-Unternehmen... ► Artikel lesen | |
ICON | 143,70 | +2,35 % | ICON plc Schedules First Quarter 2025 Earnings Conference Call | ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025... ► Artikel lesen | |
TELEFLEX | 125,00 | +3,31 % | Teleflex Announces FDA Clearance Of AC3 Range Intra-Aortic Balloon Pump | WASHINGTON (dpa-AFX) - Teleflex (TFX) announced FDA 510(k) clearance of the AC3 Range Intra-Aortic Balloon Pump. The AC3 Range IABP is designed to provide ongoing IABP support across various... ► Artikel lesen | |
DELCATH SYSTEMS | 10,900 | -6,03 % | Delcath Systems Inc. Q4 Loss Decreases, But Misses Estimates | WASHINGTON (dpa-AFX) - Delcath Systems Inc. (DCTH) reported Loss for fourth quarter that decreased from last year but missed the Street estimates.The company's bottom line totaled -$3.40 million... ► Artikel lesen | |
INSPIRE MEDICAL SYSTEMS | 124,75 | -7,46 % | Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook | MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally... ► Artikel lesen |